Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRUIT study of dalteparin plus aspirin in pregnant women with thrombophilia and prior uteroplacental insufficiency
NL-OMON20780Recruiting
- Sponsor
- Pfizer
- Start
- Jan 2000
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial in preeclampsia and intrauterine growth restriction (IUGR) comparing Dalteparin plus aspirin with Aspirin only (2 arms). Primary endpoint: Reduction of preeclampsia before 34 weeks gestational age. Started Jan 2000; status: recruiting.
02
Drugs
dalteparinaspirin
03
Conditions
preeclampsiaintrauterine growth restriction (IUGR)
Beyond the preview
Go deeper on NL-OMON20780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20780.